A tumefactive demyelinating lesion in a person with MS after five years of fingolimod

Publication date: Available online 31 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): L. Jeung, L.M.G. Smits, E.L.J. Hoogervorst, B.W. van Oosten, S.T.F.M. FrequinSummaryA 38-year-old man with relapsing remitting multiple sclerosis (RRMS) developed a tumefactive demyelinating lesion (TDL) after being clinically and radiologically stable on fingolimod for the last five years. TDLs in MS tend to occur early on in the disease and are uncommon in long-standing MS. Compared to other immune modifying drugs used in MS, there is a relatively high and still increasing number of reports describing the development of TDL under treatment with fingolimod, suggesting a causal relation.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research